Holen Sie sich die Stockscreener-App
18.79
0.43%
0.02
Schlusskurs vom Vortag:
$18.77
Offen:
$18.92
24-Stunden-Volumen:
125.98K
Relative Volume:
0.41
Marktkapitalisierung:
$714.27M
Einnahmen:
$89.06M
Nettoeinkommen (Verlust:
$-53.41M
KGV:
-12.86
EPS:
-1.4612
Netto-Cashflow:
$-42.48M
1W Leistung:
+11.14%
1M Leistung:
-11.00%
6M Leistung:
+11.47%
1J Leistung:
+13.69%
1-Tages-Spanne:
$18.60
$19.13
1-Wochen-Bereich:
$16.96
$19.20
52-Wochen-Spanne:
$10.85
$24.33
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Compare CBLL vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
18.82 | 712.18M | 89.06M | -53.41M | -42.48M | -1.4612 |
ABT
Abbott Laboratories
|
86.53 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
311.99 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.79 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.72 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.69 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Raymond James | Strong Buy |
| 2025-06-24 | Eingeleitet | BTIG Research | Buy |
| 2025-04-04 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
Ceribell CEO to present at William Blair Growth Stock Conference on June 3, 2026 - Pluang
Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference - GlobeNewswire
Earnings call transcript: Ceribell Inc. Q1 2026 misses EPS, revenue up - Investing.com Nigeria
Bank of America Securities Remains a Buy on Ceribell, Inc. (CBLL) - The Globe and Mail
Canaccord Genuity maintains Ceribell (CBLL) buy recommendation - MSN
Ceribell anticipates $112M-$116M 2026 revenue while targeting delirium NTAP of up to $2,171 per patient - MSN
CBLL Stock Price, Quote & Chart | CERIBELL INC (NASDAQ:CBLL) - ChartMill
CeriBell Sees ‘Early Innings’ Growth as Hospital Accounts and Usage Hit Records - Yahoo Finance
Ladenburg Thalmann Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Middle East Tensions Threaten Ceribell’s Supply Chain, Shipping Routes, and Margins - TipRanks
Ceribell’s Earnings Call Signals Growth Over Profits - The Globe and Mail
TD Cowen Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $29 - Moomoo
A Quick Look at Today's Ratings for Ceribell(CBLL.US), With a Forecast Between $25 to $29 - Moomoo
Canaccord lowers Ceribell stock price target on valuation compression By Investing.com - Investing.com Australia
Canaccord lowers Ceribell stock price target on valuation compression - Investing.com
Ceribell: Buy Rating Reiterated on Strong Q1 Momentum and Expanded TAM, $28 Price Target Maintained - TipRanks
Ceribell Reports First Quarter 2026 Financial Results - The Manila Times
Ceribell, Inc. (CBLL) reports Q1 loss, beats revenue estimates - MSN
CeriBell Q1 Earnings Call Highlights - inkl
CeriBell (CBLL) Q1 2026 Earnings Transcript - AOL.com
CeriBell, Inc. (CBLL) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
CeriBell Q1 Loss Widens, Revenue Rises; Lifts Full-Year Revenue Guidance - Moomoo
Ceribell Inc (NASDAQ:CBLL) Q1 Revenue Beats Estimates, Net Loss Widens, Full-Year Guidance Raised - ChartMill
CERIBELL ($CBLL) Releases Q1 2026 Earnings - Quiver Quantitative
Ceribell beats Q1 revenue estimates; lifts 2026 guidance - TradingView
(CBLL) CeriBell Now Expects 2026 Revenue Range $112M-$116M, vs. FactSet Est of $113.1M - marketscreener.com
Earnings Flash (CBLL) CeriBell Posts Q1 Per Share Loss $0.52, vs. FactSet Est of Loss $0.39 - marketscreener.com
Earnings Flash (CBLL) Ceribell, Inc. Reports Q1 Revenue $26.5M, vs. FactSet Est of $26.1M - marketscreener.com
Ceribell, Inc. Raises Revenue Guidance for the Full Year 2026 - marketscreener.com
CeriBell Inc (CBLL) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Market ... By GuruFocus - Investing.com Canada
Number of shareholders of CeriBell, Inc. – NASDAQ:CBLL - TradingView
[144] Ceribell, Inc. SEC Filing - Stock Titan
Ceribell CEO Chao Xingjuan sells $783,973 in stock By Investing.com - Investing.com South Africa
Ceribell CEO Chao Xingjuan sells $783,973 in stock - Investing.com India
Ceribell (NASDAQ: CBLL) CEO sells 39,000 shares after options exercise - Stock Titan
FMR LLC holds 4.85M CERIBELL shares (CBLL) — Amendment No.3 - Stock Titan
Earnings Preview: Ceribell to Report Financial Results Post-market on May 11 - Moomoo
Insider sells 78,000 CBLL shares and 2,084 more (CBLL) - Stock Titan
Ceribell CTO Raymond Woo sells $226,928 of CBLL common stock - Investing.com India
Ceribell CTO Raymond Woo sells $226,928 of CBLL common stock By Investing.com - Investing.com South Africa
Ceribell (NASDAQ: CBLL) CTO sells shares under 10b5-1 trading plan - Stock Titan
Ceribell to Participate in the Bank of America Securities 2026 Health Care Conference - 富途牛牛
CBLL (CBLL) Form 144 shows option-based sales and recent insider disposals - Stock Titan
CeriBell, Inc. (NASDAQ:CBLL) Sees Significant Decrease in Short Interest - MarketBeat
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):